1.1 	A bill for an act
1.2 	relating to public safety; aligning state-controlled substance schedules with 
1.3 	federal controlled substance schedules; modifying the authority of the Board of 
1.4 	Pharmacy to regulate controlled substances; providing for penalties;amending 
1.5 	Minnesota Statutes 2010, section 152.02, as amended; Minnesota Statutes 2011 
1.6 	Supplement, section 152.027, subdivision 6.
1.7 	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.8 	Section 1. Minnesota Statutes 2010, section 152.02, as amended by Laws 2011, chapter 
1.9 	53, sections 4 and 5, is amended to read:
1.10 	152.02 SCHEDULES OF CONTROLLED SUBSTANCES; 
1.11 	ADMINISTRATION OF CHAPTER.
1.12 		Subdivision 1.Five schedules. There are established five schedules of controlled 
1.13 	substances, to be known as Schedules I, II, III, IV, and V. SuchThe schedules shall 
1.14 	initially consist of the substances listed in this section by whatever official name, common 
1.15 	or usual name, chemical name, or trade name designated.
1.16 		Subd. 2.Schedule I. The following items are listed in Schedule I: (a) Schedule I 
1.17 	consists of the substances listed in this subdivision.
1.18 	(1) (b) Opiates. Unless specifically excepted or unless listed in another schedule,
1.19 	any of the following substances, including their analogs, isomers, esters, ethers, salts, and 
1.20 	salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence 
1.21 	of the analogs, isomers, esters, ethers and salts is possible within the specific chemical 
1.22 	designation: 
1.23 	(1) acetylmethadol; 
1.24 	(2) allylprodine; 
2.1 	(3) alphacetylmethadol (except levo-alphacetylmethadol, also known as 
2.2 	levomethadyl acetate); 
2.3 	(4) alphameprodine; 
2.4 	(5) alphamethadol;
2.5 	(6) alpha-methylfentanyl benzethidine; 
2.6 	(7) betacetylmethadol; 
2.7 	(8) betameprodine; 
2.8 	(9) betamethadol; 
2.9 	(10) betaprodine; 
2.10 	(11) clonitazene; 
2.11 	(12) dextromoramide; dextrorphan;
2.12 	(13) diampromide; 
2.13 	(14) diethyliambutene;
2.14 	(15) difenoxin;
2.15 	(16) dimenoxadol; 
2.16 	(17) dimepheptanol; 
2.17 	(18) dimethyliambutene; 
2.18 	(19) dioxaphetyl butyrate; 
2.19 	(20) dipipanone; 
2.20 	(21) ethylmethylthiambutene; 
2.21 	(22) etonitazene; 
2.22 	(23) etoxeridine; 
2.23 	(24) furethidine; 
2.24 	(25) hydroxypethidine; 
2.25 	(26) ketobemidone; 
2.26 	(27) levomoramide; 
2.27 	(28) levophenacylmorphan;
2.28 	(29) 3-methylfentanyl;
2.29 	(30) acetyl-alpha-methylfentanyl;
2.30 	(31) alpha-methylthiofentanyl;
2.31 	(32) benzylfentanyl beta-hydroxyfentanyl;
2.32 	(33) beta-hydroxy-3-methylfentanyl;
2.33 	(34) 3-methylthiofentanyl;
2.34 	(35) thenylfentanyl; 
2.35 	(36) thiofentanyl;
2.36 	(37) para-fluorofentanyl;
3.1 	(38) morpheridine;
3.2 	(39) 1-methyl-4-phenyl-4-propionoxypiperidine;
3.3 	(40) noracymethadol; 
3.4 	(41) norlevorphanol;
3.5 	(42)  normethadone;
3.6 	(43) norpipanone;
3.7 	(44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
3.8 	(45) phenadoxone; 
3.9 	(46) phenampromide; 
3.10 	(47) phenomorphan; 
3.11 	(48) phenoperidine; 
3.12 	(49) piritramide; 
3.13 	(50) proheptazine; 
3.14 	(51) properidine;
3.15 	(52) propiram;
3.16 	(53) racemoramide;
3.17 	(54) tilidine;
3.18 	(55) trimeperidine.
3.19 	(2) (c) Opium derivatives. Any of the following opium derivatives substances, 
3.20 	their analogs, salts, isomers, and salts of isomers, unless specifically excepted or unless 
3.21 	listed in another schedule, whenever the existence of the analogs, salts, isomers and salts 
3.22 	of isomers is possible within the specific chemical designation: 
3.23 	(1) acetorphine; 
3.24 	(2) acetyldihydrocodeine; acetylcodone;
3.25 	(3) benzylmorphine; 
3.26 	(4) codeine methylbromide; 
3.27 	(5) codeine-n-oxide; 
3.28 	(6) cyprenorphine; 
3.29 	(7) desomorphine; 
3.30 	(8) dihydromorphine;
3.31 	(9)  drotebanol;
3.32 	(10) etorphine; 
3.33 	(11) heroin; 
3.34 	(12) hydromorphinol; 
3.35 	(13) methyldesorphine; methylhydromorphine
3.36 	(14) methyldihydromorphine; 
4.1 	(15) morphine methylbromide;
4.2 	(16) morphine methylsulfonate; 
4.3 	(17) morphine-n-oxide; 
4.4 	(18) myrophine; 
4.5 	(19) nicocodeine; 
4.6 	(20) nicomorphine; 
4.7 	(21) normorphine; 
4.8 	(22) pholcodine; 
4.9 	(23) thebacon.
4.10 	(3) (d) Hallucinogens. Any material, compound, mixture or preparation which 
4.11 	contains any quantity of the following hallucinogenic substances, their analogs, salts, 
4.12 	isomers (whether optical, positional, or geometric), and salts of isomers, unless specifically 
4.13 	excepted or unless listed in another schedule, whenever the existence of the analogs, salts, 
4.14 	isomers, and salts of isomers is possible: 
4.15 	3,4-methylenedioxy amphetamine (1) methylenedioxy amphetamine; 
4.16 	3,4-methylenedioxymethamphetamine (2) methylenedioxymethamphetamine;
4.17 	(3) methylenedioxy-N-ethylamphetamine (MDEA);
4.18 	(4) n-hydroxy-methylenedioxyamphetamine;
4.19 	(5) 4-bromo-2,5-dimethoxyamphetamine (DOB); 
4.20 	(6) 2,5-dimethoxyamphetamine (2,5-DMA); 
4.21 	(7) 4-methoxyamphetamine; 
4.22 	(8) 5-methoxy-3, 4-methylenedioxy amphetamine;
4.23 	(9) alpha-ethyltryptamine;
4.24 	(10) bufotenine; 
4.25 	(11) diethyltryptamine; 
4.26 	(12) dimethyltryptamine; 
4.27 	(13) 3,4,5-trimethoxy amphetamine; 
4.28 	(14) 4-methyl-2, 5-dimethoxyamphetamine (DOM); 
4.29 	(15) ibogaine; 
4.30 	(16) lysergic acid diethylamide (LSD); marijuana;
4.31 	(17) mescaline;
4.32 	(18) parahexyl;
4.33 	(19) N-ethyl-3-piperidyl benzilate; 
4.34 	(20) N-methyl-3-piperidyl benzilate; 
4.35 	(21) psilocybin; 
4.36 	(22) psilocyn; 
5.1 	Tetrahydrocannabinols; 1-(1-(2-thienyl) cyclohexyl) piperidine (23) tenocyclidine 
5.2 	(TPCP or TCP); 
5.3 	(24) N-ethyl-1-phenyl-cyclohexylamine (PCE); 
5.4 	(25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy); 
5.5 	(26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
5.6 	(27) 4-chloro-2,5-dimethoxyamphetamine (DOC); 
5.7 	(28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
5.8 	(29) 4-iodo-2,5-dimethoxyamphetamine (DOI); 
5.9 	(30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B); 
5.10 	(31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C); 
5.11 	(32) 4-methyl-2,5-dimethoxyphenethylamine (2-CD); 
5.12 	2,5-dimethoxy-4-ethylphenethylamine, also known as (33) 
5.13 	4-ethyl-2,5-dimethoxyphenethylamine (2C-E); 
5.14 	2,5-dimethoxy-4-iodophenethylamine, also known as(34) 
5.15 	4-iodo-2,5-dimethoxyphenethylamine (2C-I); 
5.16 	(35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
5.17 	(36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
5.18 	(37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
5.19 	(38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine 
5.20 	(2-CB-FLY);
5.21 	(39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
5.22 	(40) alpha-methyltryptamine (AMT);
5.23 	(41) N,N-diisopropyltryptamine (DiPT);
5.24 	(42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
5.25 	(43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
5.26 	(44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
5.27 	(45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
5.28 	(46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
5.29 	(47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
5.30 	(48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
5.31 	(49) 5-methoxy-α-methyltryptamine (5-MeO-AMT);
5.32 	(50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
5.33 	(51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
5.34 	(52) 5-methoxy-N-methyl-N-propyltryptamine (5-MeO-MiPT);
5.35 	(53) 5-methoxy-α-ethyltryptamine (5-MeO-AET);
5.36 	(54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
6.1 	(55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
6.2 	(56) 5-methoxy-N,N-diallytryptamine (5-MeO-DALT);
6.3 	(57) methoxetamine (MXE);
6.4 	(58) 5-iodo-2-aminoindane (5-IAI);
6.5 	(59) 5,6-methylenedioxy-2-aminoindane (MDAI).
6.6 	(4) (e) Peyote, providing. All parts of the plant presently classified botanically as 
6.7 	Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract 
6.8 	from any part of the plant, and every compound, manufacture, salts, derivative, mixture, 
6.9 	or preparation of the plant, its seeds or extracts. The listing of peyote as a controlled 
6.10 	substance in Schedule I does not apply to the nondrug use of peyote in bona fide religious 
6.11 	ceremonies of the American Indian Church, and members of the American Indian Church 
6.12 	are exempt from registration. Any person who manufactures peyote for or distributes 
6.13 	peyote to the American Indian Church, however, is required to obtain federal registration 
6.14 	annually and to comply with all other requirements of law.
6.15 	(5) (f) Central nervous system depressants. Unless specifically excepted or unless 
6.16 	listed in another schedule, any material compound, mixture, or preparation which contains 
6.17 	any quantity of the following substances having a depressant effect on the central nervous 
6.18 	system, including its, their analogs, salts, isomers, and salts of isomers whenever the 
6.19 	existence of the analogs, salts, isomers, and salts of isomers is possible within the specific 
6.20 	chemical designation:
6.21 	(1) mecloqualone;
6.22 	(2) methaqualone;
6.23 	(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;
6.24 	(4) flunitrazepam.
6.25 	(6) (g) Stimulants. Unless specifically excepted or unless listed in another schedule, 
6.26 	any material compound, mixture, or preparation which contains any quantity of the 
6.27 	following substances having a stimulant effect on the central nervous system, including its, 
6.28 	their analogs, salts, isomers, and salts of isomers whenever the existence of the analogs,
6.29 	salts, isomers, and salts of isomers is possible within the specific chemical designation:
6.30 	(1) aminorex;
6.31 	(2) cathinone;
6.32 	(3) fenethylline;
6.33 	(4) methcathinone;
6.34 	(5) methylaminorex;
6.35 	(6) N,N-dimethylamphetamine;
6.36 	(7) N-benzylpiperazine (BZP);
7.1 	4-methylmethcathinone (8) methylmethcathinone (mephedrone); 
7.2 	(9) 3,4-methylenedioxy-N-methylcathinone (methylone); 
7.3 	4-methoxymethcathinone (10) methoxymethcathinone (methedrone); 
7.4 	3,4 - methylenedioxypyrovalerone (11) methylenedioxypyrovalerone  (MDPV);
7.5 	(12) fluoromethcathinone;
7.6 	(13) methylethcathinone (MEC);
7.7 	(14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
7.8 	(15) dimethylmethcathinone (DMMC);
7.9 	(16) fluoroamphetamine;
7.10 	(17) fluoromethamphetamine;
7.11 	(18) α-methylaminobutyrophenone (MABP or buphedrone);
7.12 	(19) β-keto-N-methylbenzodioxolylpropylamine (bk-MBDB or butylone);
7.13 	(20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
7.14 	(21) naphthylpyrovalerone (naphyrone);
7.15 	(22) and any other substance, except bupropion or compounds listed under a 
7.16 	different schedule, that is structurally derived from 2-aminopropan-1-one by substitution 
7.17 	at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not 
7.18 	the compound is further modified in any of the following ways:
7.19 	(i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, 
7.20 	haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring 
7.21 	system by one or more other univalent substituents;
7.22 	(ii) by substitution at the 3-position with an acyclic alkyl substituent;
7.23 	(iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or 
7.24 	methoxybenzyl groups; or
7.25 	(iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.
7.26 	(7) (h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless 
7.27 	specifically excepted or unless listed in another schedule, any natural or synthetic material, 
7.28 	compound, mixture, or preparation that contains any quantity of a substance that is a 
7.29 	cannabinoid receptor agonist, including, but not limited to, the following substances and,
7.30 	their analogs, including isomers, whether optical, positional, or geometric; esters;, ethers;,
7.31 	salts;, and salts of isomers, esters, and ethers, whenever the existence of the isomers, 
7.32 	esters, ethers, or salts is possible within the specific chemical designation:
7.33 	1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007), 
7.34 	(2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone (JWH-015), 
7.35 	1-Pentyl-3-(1-naphthoyl)indole (JWH-018), 1-hexyl-3-(naphthalen-1-oyl)indole 
7.36 	(JWH-019), 1-Butyl-3-(1-naphthoyl)indole (JWH-073), 
8.1 	4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-081), 
8.2 	4-methoxynaphthalen-1-yl-(1-pentyl-2-methylindol-3-yl)methanone 
8.3 	(JWH-098), (1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethanone 
8.4 	(JWH-200), 7-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone 
8.5 	(JWH-164), 2-(2-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-203), 
8.6 	4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-210), 
8.7 	2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-250), 
8.8 	1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398), (6aR,10aR)- 
8.9 	9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 
8.10 	tetrahydrobenzo[c]chromen-1-ol (HU-210), (R)-(+)-[2,3-Dihydro-5-methyl-3- 
8.11 	(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone 
8.12 	(WIN-55,212-2), 2-[3-hydroxycyclohexyl]- 5-(2-methyloctan-2-yl)phenol (CP47,497), 
8.13 	dimethylheptylpyran.
8.14 	(1) marijuana;
8.15 	(2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, 
8.16 	synthetic equivalents of the substances contained in the cannabis plant or in the 
8.17 	resinous extractives of the plant, or synthetic substances with similar chemical structure 
8.18 	and pharmacological activity to those substances contained in the plant or resinous 
8.19 	extract, including, but not limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans 
8.20 	tetrahydrocannabinol, and 3,4 cis or trans tetrahydrocannabinol;
8.21 	(3) synthetic cannabinoids, including the following substances:
8.22 	(i) Naphthoylindoles, which are any compounds containing a 3-(1-napthoyl)indole 
8.23 	structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, 
8.24 	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
8.25 	2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any 
8.26 	extent and whether or not substituted in the naphthyl ring to any extent. Examples of 
8.27 	naphthoylindoles include, but are not limited to:
8.28 	(A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);
8.29 	(B) 1-Butul-3-(1-naphthoyl)indole (JWH-073);
8.30 	(C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);
8.31 	(D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
8.32 	(E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);
8.33 	(F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);
8.34 	(G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
8.35 	(H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);
8.36 	(I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);
9.1 	(J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).
9.2 	(ii) Napthylmethylindoles, which are any compounds containing a 
9.3 	1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom 
9.4 	of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
9.5 	1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further 
9.6 	substituted in the indole ring to any extent and whether or not substituted in the naphthyl 
9.7 	ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:
9.8 	(A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
9.9 	(B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methan (JWH-184).
9.10 	(iii) Naphthoylpyrroles, which are any compounds containing a 
9.11 	3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the 
9.12 	pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
9.13 	1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not 
9.14 	further substituted in the pyrrole ring to any extent, whether or not substituted in the 
9.15 	naphthyl ring to any extent. Examples of naphthoylpyrroles include, but are not limited to, 
9.16 	(5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).
9.17 	(iv) Naphthylmethylindenes, which are any compounds containing a 
9.18 	naphthylideneindene structure with substitution at the 3-position of the indene 
9.19 	ring by an allkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
9.20 	1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further 
9.21 	substituted in the indene ring to any extent, whether or not substituted in the naphthyl 
9.22 	ring to any extent. Examples of naphthylemethylindenes include, but are not limited to, 
9.23 	E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).
9.24 	(v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole 
9.25 	structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, 
9.26 	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
9.27 	2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to 
9.28 	any extent, whether or not substituted in the phenyl ring to any extent. Examples of 
9.29 	phenylacetylindoles include, but are not limited to:
9.30 	(A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
9.31 	(B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
9.32 	(C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
9.33 	(D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
9.34 	(vi) Cyclohexylphenols, which are compounds containing a 
9.35 	2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position 
9.36 	of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
10.1 	1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not 
10.2 	substituted in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, 
10.3 	but are not limited to:
10.4 	(A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
10.5 	(B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol 
10.6 	(Cannabicyclohexanol or CP 47,497 C8 homologue);
10.7 	(C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl] 
10.8 	-phenol (CP 55,940).
10.9 	(vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole 
10.10 	structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, 
10.11 	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
10.12 	2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to 
10.13 	any extent and whether or not substituted in the phenyl ring to any extent. Examples of 
10.14 	benzoylindoles include, but are not limited to:
10.15 	(A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);
10.16 	(B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);
10.17 	(C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone 
10.18 	(WIN 48,098 or Pravadoline).
10.19 	(viii) Others specifically named:
10.20 	(A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) 
10.21 	-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);
10.22 	(B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) 
10.23 	-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);
10.24 	(C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de] 
10.25 	-1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2).
10.26 	(8) (i) A controlled substance analog, to the extent that it is implicitly or explicitly 
10.27 	intended for human consumption.
10.28 		Subd. 3.Schedule II. The following items are listed in (a) Schedule II: consists of 
10.29 	the substances listed in this subdivision.
10.30 	(1) (b) Unless specifically excepted or unless listed in another schedule, any of 
10.31 	the following substances whether produced directly or indirectly by extraction from 
10.32 	substances of vegetable origin or independently by means of chemical synthesis, or by a 
10.33 	combination of extraction and chemical synthesis:
10.34 	(a) (1) Opium and opiate, and any salt, compound, derivative, or preparation 
10.35 	of opium or opiate, including the following: raw opium, opium extracts, opium 
10.36 	fluid extracts, powdered opium, granulated opium, tincture of opium, apomorphine, 
11.1 	codeine, ethylmorphine, hydrocodone, hydromorphone, metopon, morphine, oxycodone, 
11.2 	oxymorphone, thebaine.
11.3 	(i) Excluding: 
11.4 	(A) apomorphine;
11.5 	(B) thebaine-derived butorphanol;
11.6 	(C) dextrophan;
11.7 	(D) nalbuphine;
11.8 	(E) nalmefene;
11.9 	(F) naloxone;
11.10 	(G) naltrexone;
11.11 	(H) and their respective salts;
11.12 	(ii) but including the following:
11.13 	(A) opium, in all forms and extracts;
11.14 	(B) codeine;
11.15 	(C) dihydroetorphine;
11.16 	(D) ethylmorphine;
11.17 	(E) etorphine hydrochloride;
11.18 	(F) hydrocodone;
11.19 	(G) hydromorphone;
11.20 	(H) metopon;
11.21 	(I) morphine;
11.22 	(J) oxycodone;
11.23 	(K) oxymorphone;
11.24 	(L) thebaine;
11.25 	(M) oripavine;
11.26 	(b) (2) any salt, compound, derivative, or preparation thereof which is chemically 
11.27 	equivalent or identical with any of the substances referred to in clause (a) (1), except that 
11.28 	these substances shall not include the isoquinoline alkaloids of opium.;
11.29 	(c) (3) opium poppy and poppy straw.;
11.30 	(d) (4) coca leaves and any salt, cocaine compound, derivative, or preparation 
11.31 	of coca leaves, including cocaine and ecgonine, the salts and isomers of cocaine and 
11.32 	ecgonine, and the salts of their isomers. (including cocaine and ecgonine and their salts, 
11.33 	isomers, derivatives, and salts of isomers and derivatives), and any salt, compound, 
11.34 	derivative, or preparation thereof which is chemically equivalent or identical with any of 
11.35 	these substances, except that the substances shall not include decocainized coca leaves or 
11.36 	extraction of coca leaves, which extractions do not contain cocaine or ecgonine;
12.1 	(e) Any salt, compound, derivative, or preparation thereof which is chemically 
12.2 	equivalent or identical with any of the substances referred to in clause (d), except that 
12.3 	the substances shall not include decocainized coca leaves or extraction of coca leaves, 
12.4 	which extractions do not contain cocaine or ecgonine. (5) concentrate of poppy straw (the 
12.5 	crude extract of poppy straw in either liquid, solid, or powder form which contains the 
12.6 	phenanthrene alkaloids of the opium poppy).
12.7 	(2) (c) Any of the following opiates, including their isomers, esters, ethers, salts, and 
12.8 	salts of isomers, esters and ethers, unless specifically excepted, or unless listed in another 
12.9 	schedule, whenever the existence of such isomers, esters, ethers and salts is possible 
12.10 	within the specific chemical designation: 
12.11 	(1) alfentanil; 
12.12 	(2) alphaprodine; 
12.13 	(3) anileridine; 
12.14 	(4) bezitramide;
12.15 	(5) bulk dextropropoxyphene (nondosage forms);
12.16 	(6) carfentanil;
12.17 	(7) dihydrocodeine; 
12.18 	(8) dihydromorphinone; 
12.19 	(9) diphenoxylate; 
12.20 	(10) fentanyl; 
12.21 	(11) isomethadone;
12.22 	(12) levo-alpha-acetylmethadol (LAAM) levomethorphan; 
12.23 	(13) levorphanol; 
12.24 	(14) metazocine; 
12.25 	(15) methadone; 
12.26 	(16) methadone - intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane; 
12.27 	(17) moramide - intermediate, 2-methyl-3-morpholino-1, 
12.28 	1-diphenyl-propane-carboxylic acid; 
12.29 	(18) pethidine; 
12.30 	(19) pethidine - intermediate - a, 4-cyano-1-methyl-4-phenylpiperidine; 
12.31 	(20) pethidine - intermediate - b, ethyl-4-phenylpiperidine-4-carboxylate; 
12.32 	(21) pethidine - intermediate - c, 1-methyl-4-phenylpiperidine-4-carboxylic acid; 
12.33 	(22) phenazocine; 
12.34 	(23) piminodine; 
12.35 	(24) racemethorphan; 
12.36 	(25) racemorphan;
13.1 	(26) remifentanil; 
13.2 	(27) sufentanil;
13.3 	(28) tapentadol.
13.4 	(3) (d) Unless specifically excepted or unless listed in another schedule, any 
13.5 	material, compound, mixture, or preparation which contains any quantity of the following 
13.6 	substances having a stimulant effect on the central nervous system:
13.7 	(a) (1) amphetamine, its salts, optical isomers, and salts of its optical isomers;
13.8 	(b) (2) methamphetamine, its salts, isomers, and salts of its isomers;
13.9 	(c) (3) phenmetrazine and its salts;
13.10 	(d) (4) methylphenidate;
13.11 	(5) lisdexamfetamine.
13.12 	(4) (e) Unless specifically excepted or unless listed in another schedule, any 
13.13 	material, compound, mixture, or preparation which contains any quantity of the following 
13.14 	substances having a depressant effect on the central nervous system, including its salts, 
13.15 	isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of 
13.16 	isomers is possible within the specific chemical designation:
13.17 	(a) methaqualone
13.18 	(b) (1) amobarbital;
13.19 	(2) glutethimide;
13.20 	(c) (3) secobarbital;
13.21 	(d) (4) pentobarbital;
13.22 	(e) (5) phencyclidine;
13.23 	(f) (6) phencyclidine immediate precursors:
13.24 	(i) 1-phenylcyclohexylamine;
13.25 	(ii) 1-piperidinocyclohexanecarbonitrile;
13.26 	(7) phenylacetone.
13.27 	(f) Hallucinogenic substances: nabilone.
13.28 		Subd. 4.Schedule III. The following items are listed in (a) Schedule III: consists of 
13.29 	the substances listed in this subdivision.
13.30 	(1) Any material, compound, mixture, or preparation which contains any quantity of 
13.31 	Amphetamine, its salts, optical isomers, and salts of its optical isomers; Phenmetrazine 
13.32 	and its salts; Methamphetamine, its salts, isomers, and salts of isomers; Methylphenidate; 
13.33 	and which is required by federal law to be labeled with the symbol prescribed by 21 Code 
13.34 	of Federal Regulations Section 1302.03 and in effect on February 1, 1976 designating that 
13.35 	the drug is listed as a Schedule III controlled substance under federal law. (b) Stimulants. 
13.36 	Unless specifically excepted or unless listed in another schedule, any material, compound, 
14.1 	mixture, or preparation which contains any quantity of the following substances having 
14.2 	a potential for abuse associated with a stimulant effect on the central nervous system, 
14.3 	including its salts, isomers, and salts of such isomers whenever the existence of such salts, 
14.4 	isomers, and salts of isomers is possible within the specific chemical designation: 
14.5 	(1) benzphetamine; 
14.6 	(2) chlorphentermine; 
14.7 	(3) clortermine; 
14.8 	(4) phendimetrazine.
14.9 	(2) (c) Depressants. Unless specifically excepted or unless listed in another schedule,
14.10 	any material, compound, mixture, or preparation which contains any quantity of the 
14.11 	following substances having a potential for abuse associated with a depressant effect on 
14.12 	the central nervous system:
14.13 	(a) (1) any compound, mixture, or preparation containing amobarbital, secobarbital, 
14.14 	pentobarbital or any salt thereof and one or more other active medicinal ingredients which 
14.15 	are not listed in any schedule.;
14.16 	(b) (2) any suppository dosage form containing amobarbital, secobarbital, 
14.17 	pentobarbital, or any salt of any of these drugs and approved by the food and drug 
14.18 	administration for marketing only as a suppository.;
14.19 	(c) (3) any substance which contains any quantity of a derivative of barbituric acid, 
14.20 	or any salt of a derivative of barbituric acid, except those substances which are specifically 
14.21 	listed in other schedules: Chlorhexadol; Glutethimide; Lysergic acid; Lysergic acid amide; 
14.22 	Methyprylon; Sulfondiethylmethane; Sulfonethylmethane; Sulfonmethane.;
14.23 	(d) Gamma hydroxybutyrate, any salt, compound, derivative, or preparation of 
14.24 	gamma hydroxybutyrate, including any isomers, esters, and ethers and salts of isomers, 
14.25 	esters, and ethers of gamma hydroxybutyrate whenever the existence of such isomers, 
14.26 	esters, and salts is possible within the specific chemical designation. (4) any drug product 
14.27 	containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, 
14.28 	for which an application is approved under section 505 of the federal Food, Drug, and 
14.29 	Cosmetic Act;
14.30 	(5) any of the following substances: 
14.31 	(i) chlorhexadol;
14.32 	(ii) ketamine, its salts, isomers and salts of isomers;
14.33 	(iii) lysergic acid;
14.34 	(iv) lysergic acid amide;
14.35 	(v) methyprylon;
14.36 	(vi) sulfondiethylmethane;
15.1 	(vii) sulfonenthylmethane;
15.2 	(viii) sulfonmethane;
15.3 	(ix) tiletamine and zolazepam and any salt thereof;
15.4 	(x) embutramide.
15.5 	(3) Any material, compound, mixture, or preparation which contains any quantity of 
15.6 	the following substances having a potential for abuse associated with a stimulant effect on 
15.7 	the central nervous system:
15.8 	(a) Benzphetamine
15.9 	(b) Chlorphentermine
15.10 	(c) Clortermine
15.11 	(d) Mazindol
15.12 	(e) Phendimetrazine.
15.13 	(4) (d) Nalorphine.
15.14 	(5) Any material, compound, mixture, or preparation containing limited quantities 
15.15 	of any of the following narcotic drugs, or any salts thereof (e) Narcotic drugs. Unless 
15.16 	specifically excepted or unless listed in another schedule, any material, compound, 
15.17 	mixture, or preparation containing any of the following narcotic drugs, or their salts 
15.18 	calculated as the free anhydrous base or alkaloid, in limited quantities as follows:
15.19 	(a)(1) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 
15.20 	milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid 
15.21 	of opium.;
15.22 	(b)(2) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 
15.23 	milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized 
15.24 	therapeutic amounts.;
15.25 	(c)(3) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or 
15.26 	not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an 
15.27 	isoquinoline alkaloid of opium.;
15.28 	(d)(4) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not 
15.29 	more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients 
15.30 	in recognized therapeutic amounts.;
15.31 	(e)(5) not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more 
15.32 	than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in 
15.33 	recognized therapeutic amounts.;
15.34 	(f)(6) not more than 300 milligrams of ethylmorphine per 100 milliliters or not more 
15.35 	than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in 
15.36 	recognized therapeutic amounts.;
16.1 	(g)(7) not more than 500 milligrams of opium per 100 milliliters or per 100 grams, 
16.2 	or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic 
16.3 	ingredients in recognized therapeutic amounts.;
16.4 	(h)(8) not more than 50 milligrams of morphine per 100 milliliters or per 100 grams 
16.5 	with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.;
16.6 	(6)(f)  Anabolic steroids, which and human growth hormone.
16.7 	(1) Anabolic steroids, for purposes of this subdivision, means any drug or 
16.8 	hormonal substance, chemically and pharmacologically related to testosterone, other 
16.9 	than estrogens, progestins, corticosteroids, and dehydroepiandrosterone, and includes: 
16.10 	androstanediol; androstanedione; androstenediol; androstenedione; bolasterone; 
16.11 	boldenone; calusterone; chlorotestosterone; chorionic gonadotropin; clostebol; 
16.12 	dehydrochloromethyltestosterone; (triangle)1-dihydrotestosterone; 4-dihydrotestosterone; 
16.13 	drostanolone; ethylestrenol; fluoxymesterone; formebolone; furazabol; human 
16.14 	growth hormones; 13b-ethyl-17a-hydroxygon-4-en-3-one; 4-hydroxytestosterone; 
16.15 	4-hydroxy-19-nortestosterone; mestanolone; mesterolone; methandienone; 
16.16 	methandranone; methandriol; methandrostenolone; methenolone; 17a-methyl-3b, 
16.17 	17b-dihydroxy-5a-androstane; 17a-methyl-3a, 17b-dihydroxy-5a-androstane; 
16.18 	17a-methyl-3b, 17b-dihydroxyandrost-4-ene; 17a-methyl-4-hydroxynandrolone; 
16.19 	methyldienolone; methyltrienolone; methyltestosterone; mibolerone; 
16.20 	17a-methyl-(triangle)1-dihydrotestosterone; nandrolone; nandrolone phenpropionate; 
16.21 	norandrostenediol; norandrostenedione; norbolethone; norclostebol; norethandrolone; 
16.22 	normethandrolone; oxandrolone; oxymesterone; oxymetholone; stanolone; stanozolol; 
16.23 	stenbolone; testolactone; testosterone; testosterone propionate; tetrahydrogestrinone; 
16.24 	trenbolone; and any salt, ester, or ether of a drug or substance described in this paragraph.
16.25 	(i) 3[beta],17[beta]-dihydroxy-5[alpha]-androstane;
16.26 	(ii) 3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;
16.27 	(iii) androstanedione (5[alpha]-androstan-3,17-dione);
16.28 	(iv) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-l-ene;
16.29 	(v) 3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene);
16.30 	(vi) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene);
16.31 	(vii) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene);
16.32 	(viii) 1-androstenedione (5[alpha]-androst-1-en-3,17-dione);
16.33 	(ix) 4-androstenedione (androst-4-en-3,17-dione);
16.34 	(x) 5-androstenedione (androst-5-en-3,17-dione);
16.35 	(xi) bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);
16.36 	(xii) boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one);
17.1 	(xiii) boldione (androsta-1,4-diene-3,17-dione);
17.2 	(xiv) calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);
17.3 	(xv) clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one);
17.4 	(xvi) dehydrochloromethyltestosterone 
17.5 	(4-chloro-17[beta]-hydroxy-17[alpha]-methylandrost-1,4-dien-3-one);
17.6 	(xvii) desoxymethyltestosterone 
17.7 	(17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol);
17.8 	(xviii) [delta]1-dihydrotestosterone- 
17.9 	(17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);
17.10 	(xix) 4-dihydrotestosterone (17[beta]-hydroxy-androstan-3-one);
17.11 	(xx) drostanolone (17[beta]hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one);
17.12 	(xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene);
17.13 	(xxii) fluoxymesterone 
17.14 	(9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one);
17.15 	(xxiii) formebolone 
17.16 	(2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one);
17.17 	(xxiv) furazabol 
17.18 	(17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan)13[beta]-ethyl-17[beta] 
17.19 	-hydroxygon-4-en-3-one;
17.20 	(xxv) 4-hydroxytestosterone (4,17[beta]-dihydroxyandrost-4-en-3-one);
17.21 	(xxvi) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one);
17.22 	(xxvii) mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one);
17.23 	(xxviii) mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one);
17.24 	(xxix) methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-dien-3-one);
17.25 	(xxx) methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene);
17.26 	(xxxi) methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);
17.27 	(xxxii) 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5[alpha]-androstane;
17.28 	(xxxiii) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;
17.29 	(xxxiv) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene;
17.30 	(xxxv) 17[alpha]-methyl-4-hydroxynandrolone 
17.31 	(17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);
17.32 	(xxxvi) methyldienolone 
17.33 	(17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one);
17.34 	(xxxvii) methyltrienolone 
17.35 	(17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one);
18.1 	(xxxviii) methyltestosterone 
18.2 	(17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one);
18.3 	(xxxix) mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one);
18.4 	(xl) 17[alpha]-methyl-[delta]1-dihydrotestosterone 
18.5 	(17[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one);
18.6 	(xli) nandrolone (17[beta]-hydroxyestr-4-en-3-one);
18.7 	(xlii) 19-nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene;
18.8 	(xliii) 3[alpha],17[beta]-dihydroxyestr-4-ene); 19-nor-5-androstenediol 
18.9 	(3[beta],17[beta]-dihydroxyestr-5-ene;
18.10 	(xliv) 3[alpha],17[beta]-dihydroxyestr-5-ene);
18.11 	(xlv) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);
18.12 	(xlvi) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
18.13 	(xlvii) norbolethone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one);
18.14 	(xlviii) norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one);
18.15 	(xlix) norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one);
18.16 	(l) normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one);
18.17 	(li) oxandrolone 
18.18 	(17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one);
18.19 	(lii) oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one);
18.20 	(liii) oxymetholone 
18.21 	(17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-5[alpha]-androstan-3-one);
18.22 	(liv) stanozolol 
18.23 	(17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-2-eno[3,2-c]-pyrazole);
18.24 	(lv) stenbolone (17[beta]-hydroxy-2-methyl-5[alpha]-androst-1-en-3-one);
18.25 	(lvi) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid 
18.26 	lactone);
18.27 	(lvii) testosterone (17[beta]-hydroxyandrost-4-en-3-one);
18.28 	(lviii) tetrahydrogestrinone 
18.29 	(13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4,9,11-trien-3-one);
18.30 	(lix) trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one);
18.31 	(lx) any salt, ester, or ether of a drug or substance described in this paragraph.
18.32 	Anabolic steroids are not included if they are: (i) (A) expressly intended for administration 
18.33 	through implants to cattle or other nonhuman species; and (ii) (B) approved by the United 
18.34 	States Food and Drug Administration for that use.;
18.35 	(2) Human growth hormones.
19.1 	(g) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and 
19.2 	encapsulated in a soft gelatin capsule in a United States Food and Drug Administration 
19.3 	approved product.
19.4 	(h) Any material, compound, mixture, or preparation containing the following 
19.5 	narcotic drug or its salt: buprenorphine.
19.6 		Subd. 5.Schedule IV. The following items are listed in Schedule IV: Barbital; 
19.7 	Butorphanol; Chloral betaine; Chloral hydrate; Chlordiazepoxide; Clonazepam; 
19.8 	Clorazepate; Diazepam; Diethylpropion; Ethchlorvynol; Ethinamate; Fenfluramine; 
19.9 	Flurazepam; Mebutamate; Methohexital; Meprobamate except when in combination with 
19.10 	the following drugs in the following or lower concentrations: conjugated estrogens, 0.4 
19.11 	mg; tridihexethyl chloride, 25mg; pentaerythritol tetranitrate, 20 mg; Methylphenobarbital; 
19.12 	Oxazepam; Paraldehyde; Pemoline; Petrichloral; Phenobarbital; and Phentermine (a) 
19.13 	Schedule IV consists of the substances listed in this subdivision.
19.14 	(b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, 
19.15 	any material, compound, mixture, or preparation containing any of the following narcotic 
19.16 	drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities 
19.17 	as follows:
19.18 	(1) not more than one milligram of difenoxin and not less than 25 micrograms of 
19.19 	atropine sulfate per dosage unit;
19.20 	(2) dextropropoxyphene (Darvon and Darvocet).
19.21 	(c) Depressants. Unless specifically excepted or unless listed in another schedule, 
19.22 	any material, compound, mixture, or preparation containing any quantity of the following 
19.23 	substances, including its salts, isomers, and salts of isomers whenever the existence of the 
19.24 	salts, isomers, and salts of isomers is possible: 
19.25 	(1) alprazolam;
19.26 	(2) barbital;
19.27 	(3) bromazepam;
19.28 	(4) camazepam;
19.29 	(5) carisoprodol;
19.30 	(6) chloral betaine;
19.31 	(7) chloral hydrate;
19.32 	(8) chlordiazepoxide;
19.33 	(9) clobazam;
19.34 	(10) clonazepam;
19.35 	(11) clorazepate;
19.36 	(12) clotiazepam;
20.1 	(13) cloxazolam;
20.2 	(14) delorazepam;
20.3 	(15) diazepam;
20.4 	(16) dichloralphenazone;
20.5 	(17) estazolam;
20.6 	(18) ethchlorvynol;
20.7 	(19) ethinamate;
20.8 	(20) ethyl loflazepate;
20.9 	(21) fludiazepam;
20.10 	(22) flurazepam;
20.11 	(23) halazepam;
20.12 	(24) haloxazolam;
20.13 	(25) ketazolam;
20.14 	(26) loprazolam;
20.15 	(27) lorazepam;
20.16 	(28) lormetazepam mebutamate;
20.17 	(29) medazepam;
20.18 	(30) meprobamate;
20.19 	(31) methohexital;
20.20 	(32) methylphenobarbital;
20.21 	(33) midazolam;
20.22 	(34) nimetazepam;
20.23 	(35) nitrazepamnordiazepam;
20.24 	(36) oxazepam;
20.25 	(37) oxazolam;
20.26 	(38) paraldehydepetrichloral;
20.27 	(39) phenobarbital;
20.28 	(40) pinazepam;
20.29 	(41) prazepam;
20.30 	(42) quazepam;
20.31 	(43) temazepam;
20.32 	(44) tetrazepam;
20.33 	(45) triazolam;
20.34 	(46) zaleplon;
20.35 	(47) zolpidem;
20.36 	(48) zopiclone.
21.1 	(d) Any material, compound, mixture, or preparation which contains any quantity of 
21.2 	the following substance including its salts, isomers, and salts of such isomers, whenever 
21.3 	the existence of such salts, isomers, and salts of isomers is possible: fenfluramine.
21.4 	(e) Stimulants. Unless specifically excepted or unless listed in another schedule, 
21.5 	any material, compound, mixture, or preparation which contains any quantity of the 
21.6 	following substances having a stimulant effect on the central nervous system, including its 
21.7 	salts, isomers, and salts of isomers:
21.8 	(1) cathine (norpseudoephedrine);
21.9 	(2) diethylpropion;
21.10 	(3) fencamfamine;
21.11 	(4) fenproporex;
21.12 	(5) mazindol;
21.13 	(6) mefenorex;
21.14 	(7) modafinil;
21.15 	(8) pemoline (including organometallic complexes and chelates thereof);
21.16 	(9) phentermine;
21.17 	(10) pipradol;
21.18 	(11) sibutramine;
21.19 	(12) SPA (1-dimethylamino-1,2-diphenylethane).
21.20 		Subd. 6.Schedule V; restrictions on methamphetamine precursor drugs. (a) As 
21.21 	used in this subdivision, the following terms have the meanings given:
21.22 	(1) "methamphetamine precursor drug" means any compound, mixture, or 
21.23 	preparation intended for human consumption containing ephedrine or pseudoephedrine as 
21.24 	its sole active ingredient or as one of its active ingredients; and
21.25 	(2) "over-the-counter sale" means a retail sale of a drug or product but does not 
21.26 	include the sale of a drug or product pursuant to the terms of a valid prescription.
21.27 	(b) The following items are listed in Schedule V:
21.28 	(1) any compound, mixture, or preparation containing any of the following limited 
21.29 	quantities of narcotic drugs, which shall include one or more nonnarcotic active medicinal 
21.30 	ingredients in sufficient proportion to confer upon the compound, mixture or preparation 
21.31 	valuable medicinal qualities other than those possessed by the narcotic drug alone:
21.32 	(i) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 
21.33 	grams;
21.34 	(ii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 
21.35 	grams;
22.1 	(iii) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms 
22.2 	of atropine sulfate per dosage unit; or
22.3 	(iv) not more than 15 milligrams of anhydrous morphine per 100 milliliters or per 
22.4 	100 grams; and 100 milligrams of opium per 100 milliliters or per 100 grams; or
22.5 	(v) not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of 
22.6 	atropine sulfate per dosage unit.
22.7 	(2) Stimulants. Unless specifically exempted or excluded or unless listed in another 
22.8 	schedule, any material, compound, mixture, or preparation that contains any quantity of 
22.9 	the following substance having a stimulant effect on the central nervous system, including 
22.10 	its salts, isomers, and salts of isomers: pyrovalerone.
22.11 	(3) Depressants. Unless specifically exempted or excluded or unless listed in another 
22.12 	schedule, any material, compound, mixture, or preparation that contains any quantity 
22.13 	of the following substance having a depressant effect on the central nervous system, 
22.14 	including its salts, isomers, and salts of isomers:
22.15 	(i) pregabalin;
22.16 	(ii) lacosamide.
22.17 	(2) (4) Any compound, mixture, or preparation containing ephedrine or 
22.18 	pseudoephedrine as its sole active ingredient or as one of its active ingredients.
22.19 	(c) No person may sell in a single over-the-counter sale more than two packages 
22.20 	of a methamphetamine precursor drug or a combination of methamphetamine precursor 
22.21 	drugs or any combination of packages exceeding a total weight of six grams, calculated as 
22.22 	the base.
22.23 	(d) Over-the-counter sales of methamphetamine precursor drugs are limited to:
22.24 	(1) packages containing not more than a total of three grams of one or 
22.25 	more methamphetamine precursor drugs, calculated in terms of ephedrine base or 
22.26 	pseudoephedrine base; or
22.27 	(2) for nonliquid products, sales in blister packs, where each blister contains not 
22.28 	more than two dosage units, or, if the use of blister packs is not technically feasible, sales 
22.29 	in unit dose packets or pouches.
22.30 	(e) A business establishment that offers for sale methamphetamine precursor drugs 
22.31 	in an over-the-counter sale shall ensure that all packages of the drugs are displayed 
22.32 	behind a checkout counter where the public is not permitted and are offered for sale only 
22.33 	by a licensed pharmacist, a registered pharmacy technician, or a pharmacy clerk. The 
22.34 	establishment shall ensure that the person making the sale requires the buyer:
22.35 	(1) to provide photographic identification showing the buyer's date of birth; and
23.1 	(2) to sign a written or electronic document detailing the date of the sale, the name 
23.2 	of the buyer, and the amount of the drug sold.
23.3 	A document described under clause (2) must be retained by the establishment for 
23.4 	at least three years and must at all reasonable times be open to the inspection of any 
23.5 	law enforcement agency.
23.6 	Nothing in this paragraph requires the buyer to obtain a prescription for the drug's 
23.7 	purchase.
23.8 	(f) No person may acquire through over-the-counter sales more than six grams of 
23.9 	methamphetamine precursor drugs, calculated as the base, within a 30-day period.
23.10 	(g) No person may sell in an over-the-counter sale a methamphetamine precursor 
23.11 	drug to a person under the age of 18 years. It is an affirmative defense to a charge under 
23.12 	this paragraph if the defendant proves by a preponderance of the evidence that the 
23.13 	defendant reasonably and in good faith relied on proof of age as described in section 
23.14 	340A.503, subdivision 6.
23.15 	(h) A person who knowingly violates paragraph (c), (d), (e), (f), or (g) is guilty of 
23.16 	a misdemeanor and may be sentenced to imprisonment for not more than 90 days, or to 
23.17 	payment of a fine of not more than $1,000, or both.
23.18 	(i) An owner, operator, supervisor, or manager of a business establishment that 
23.19 	offers for sale methamphetamine precursor drugs whose employee or agent is convicted of 
23.20 	or charged with violating paragraph (c), (d), (e), (f), or (g) is not subject to the criminal 
23.21 	penalties for violating any of those paragraphs if the person:
23.22 	(1) did not have prior knowledge of, participate in, or direct the employee or agent to 
23.23 	commit the violation; and
23.24 	(2) documents that an employee training program was in place to provide the 
23.25 	employee or agent with information on the state and federal laws and regulations regarding 
23.26 	methamphetamine precursor drugs.
23.27 	(j) Any person employed by a business establishment that offers for sale 
23.28 	methamphetamine precursor drugs who sells such a drug to any person in a suspicious 
23.29 	transaction shall report the transaction to the owner, supervisor, or manager of the 
23.30 	establishment. The owner, supervisor, or manager may report the transaction to local law 
23.31 	enforcement. A person who reports information under this subdivision in good faith is 
23.32 	immune from civil liability relating to the report.
23.33 	(k) Paragraphs (b) to (j) do not apply to:
23.34 	(1) pediatric products labeled pursuant to federal regulation primarily intended for 
23.35 	administration to children under 12 years of age according to label instructions;
24.1 	(2) methamphetamine precursor drugs that are certified by the Board of Pharmacy as 
24.2 	being manufactured in a manner that prevents the drug from being used to manufacture 
24.3 	methamphetamine;
24.4 	(3) methamphetamine precursor drugs in gel capsule or liquid form; or
24.5 	(4) compounds, mixtures, or preparations in powder form where pseudoephedrine 
24.6 	constitutes less than one percent of its total weight and is not its sole active ingredient.
24.7 	(l) The Board of Pharmacy, in consultation with the Department of Public Safety, 
24.8 	shall certify methamphetamine precursor drugs that meet the requirements of paragraph 
24.9 	(k), clause (2), and publish an annual listing of these drugs.
24.10 	(m) Wholesale drug distributors licensed and regulated by the Board of Pharmacy 
24.11 	pursuant to sections 151.42 to 151.51 and registered with and regulated by the United 
24.12 	States Drug Enforcement Administration are exempt from the methamphetamine precursor 
24.13 	drug storage requirements of this section.
24.14 	(n) This section preempts all local ordinances or regulations governing the sale 
24.15 	by a business establishment of over-the-counter products containing ephedrine or 
24.16 	pseudoephedrine. All ordinances enacted prior to the effective date of this act are void.
24.17 		Subd. 7.Board of Pharmacy; regulation of substances. The Board of Pharmacy 
24.18 	is authorized to regulate and define additional substances which contain quantities of a 
24.19 	substance possessing abuse potential in accordance with the following criteria:
24.20 	(1) The Board of Pharmacy shall place a substance in Schedule I if it finds that the 
24.21 	substance has: A high potential for abuse, no currently accepted medical use in the United 
24.22 	States, and a lack of accepted safety for use under medical supervision.
24.23 	(2) The Board of Pharmacy shall place a substance in Schedule II if it finds that the 
24.24 	substance has: A high potential for abuse, currently accepted medical use in the United 
24.25 	States, or currently accepted medical use with severe restrictions, and that abuse may lead 
24.26 	to severe psychological or physical dependence.
24.27 	(3) The Board of Pharmacy shall place a substance in Schedule III if it finds that the 
24.28 	substance has: A potential for abuse less than the substances listed in Schedules I and II, 
24.29 	currently accepted medical use in treatment in the United States, and that abuse may lead 
24.30 	to moderate or low physical dependence or high psychological dependence.
24.31 	(4) The Board of Pharmacy shall place a substance in Schedule IV if it finds that 
24.32 	the substance has: A low potential for abuse relative to the substances in Schedule III, 
24.33 	currently accepted medical use in treatment in the United States, and that abuse may lead 
24.34 	to limited physical dependence or psychological dependence relative to the substances in 
24.35 	Schedule III.
25.1 	(5) The Board of Pharmacy shall place a substance in Schedule V if it finds that the 
25.2 	substance has: A low potential for abuse relative to the substances listed in Schedule IV, 
25.3 	currently accepted medical use in treatment in the United States, and limited physical 
25.4 	dependence and/or psychological dependence liability relative to the substances listed 
25.5 	in Schedule IV.
25.6 		Subd. 8.Add, delete, or reschedule substances. The state Board of Pharmacy may, 
25.7 	by rule, add substances to or delete or reschedule substances listed in this section. The 
25.8 	Board of Pharmacy may not delete or reschedule a drug that is in Schedule I, except as 
25.9 	provided in subdivision 12.
25.10 	In making a determination regarding a substance, the Board of Pharmacy shall 
25.11 	consider the following: The actual or relative potential for abuse, the scientific evidence 
25.12 	of its pharmacological effect, if known, the state of current scientific knowledge 
25.13 	regarding the substance, the history and current pattern of abuse, the scope, duration, 
25.14 	and significance of abuse, the risk to public health, the potential of the substance to 
25.15 	produce psychic or physiological dependence liability, and whether the substance is an 
25.16 	immediate precursor of a substance already controlled under this section. The state Board 
25.17 	of Pharmacy may include any nonnarcotic drug authorized by federal law for medicinal 
25.18 	use in a schedule only if such drug must, under either federal or state law or rule, be 
25.19 	sold only on prescription.
25.20 		Subd. 8a.Methamphetamine precursors Board of Pharmacy; expedited 
25.21 	scheduling of additional substances. The State Board of Pharmacy may, by order, require 
25.22 	that nonprescription ephedrine or pseudophedrine products sold in gel capsule or liquid 
25.23 	form be subject to the sale restrictions established in subdivision 6 for methamphetamine 
25.24 	precursor drugs, if the board concludes that ephedrine or pseudophedrine products in gel 
25.25 	capsule or liquid form can be used to manufacture methamphetamine. In assessing the 
25.26 	need for an order under this subdivision, the board shall consult at least annually with the 
25.27 	advisory council on controlled substances, the commissioner of public safety, and the 
25.28 	commissioner of health. The state Board of Pharmacy may, by rule, add a substance to 
25.29 	Schedule I provided that it finds that the substance has a high potential for abuse, no 
25.30 	currently accepted medical use in the United States, a lack of accepted safety for use under 
25.31 	medical supervision, known adverse health effects and is currently available for use within 
25.32 	the state. For the purposes of this subdivision only, the board may use the expedited 
25.33 	rulemaking process under section 14.389.
25.34 		Subd. 9.Except substances by rule. The state Board of Pharmacy may by rule 
25.35 	except any compound, mixture, or preparation containing any stimulant or depressant 
25.36 	substance listed in subdivision 4, clauses (1) and (2) paragraphs (b) and (c), or in 
26.1 	subdivisions 5 and 6 from the application of all or any part of this chapter, if the 
26.2 	compound, mixture, or preparation contains one or more active medicinal ingredients not 
26.3 	having a stimulant or depressant effect on the central nervous system; provided, that 
26.4 	such admixtures shall be included therein in such combinations, quantity, proportion, 
26.5 	or concentration as to vitiate the potential for abuse of the substances which do have a 
26.6 	stimulant or depressant effect on the central nervous system.
26.7 		Subd. 10.Dextromethorphan. Dextromethorphan shall not be deemed to be 
26.8 	included in any schedule by reason of the enactment of Laws 1971, chapter 937, unless 
26.9 	controlled pursuant to the foregoing provisions of this section.
26.10 		Subd. 12.Coordination of controlled substance regulation with federal law and 
26.11 	state statute. If any substance is designated, rescheduled, or deleted as a controlled 
26.12 	substance under federal law and notice thereof is given to the state Board of Pharmacy, the 
26.13 	state Board of Pharmacy shall similarly control the substance under this chapter, after the 
26.14 	expiration of 30 days from publication in the Federal Register of a final order designating 
26.15 	a substance as a controlled substance or rescheduling or deleting a substance. Such order 
26.16 	shall be filed with the secretary of state. If within that 30-day period, the state Board of 
26.17 	Pharmacy objects to inclusion, rescheduling, or deletion, it shall publish the reasons for 
26.18 	objection and afford all interested parties an opportunity to be heard. At the conclusion of 
26.19 	the hearing, the state Board of Pharmacy shall publish its decision, which shall be subject 
26.20 	to the provisions of chapter 14.
26.21 	In exercising the authority granted by this chapter, the state Board of Pharmacy shall 
26.22 	be subject to the provisions of chapter 14. The state Board of Pharmacy shall provide 
26.23 	copies of any proposed rule under this chapter to the advisory council on controlled 
26.24 	substances at least 30 days prior to any hearing required by section 14.14, subdivision 1. 
26.25 	The state Board of Pharmacy shall consider the recommendations of the advisory council 
26.26 	on controlled substances, which may be made prior to or at the hearing.
26.27 	The state Board of Pharmacy shall annually submit a report to the legislature on or 
26.28 	before December 1 that specifies what changes the board made to the controlled substance 
26.29 	schedules maintained by the board in Minnesota Rules, parts 6800.4210 to 6800.4250, in 
26.30 	the preceding 12 months. The report must include specific recommendations for amending 
26.31 	the controlled substance schedules contained in subdivisions 2 to 6, so that they conform 
26.32 	with the controlled substance schedules maintained by the board in Minnesota Rules, 
26.33 	parts 6800.4210 to 6800.4250.
26.34 		Subd. 13.Implementation study. Annually, the state Board of Pharmacy shall study 
26.35 	the implementation of this chapter in relation to the problems of drug abuse in Minnesota.

27.1 	EFFECTIVE DATE. This section is effective August 1, 2012, and applies to crimes 
27.2 	committed on or after that date.

27.3 	Sec. 2. Minnesota Statutes 2011 Supplement, section 152.027, subdivision 6, is 
27.4 	amended to read:
27.5 		Subd. 6.Sale or possession of synthetic cannabinoids. (a) As used in this 
27.6 	subdivision, "synthetic cannabinoid" includes any substance included in section 152.02, 
27.7 	subdivision 2, paragraph (h), clause (7) (iii).
27.8 	(b) A person who unlawfully sells a synthetic cannabinoid for no remuneration is 
27.9 	guilty of a gross misdemeanor.
27.10 	(c) A person who unlawfully sells any amount of a synthetic cannabinoid is guilty of 
27.11 	a gross misdemeanor felony and if convicted may be sentenced to imprisonment for not 
27.12 	more than five years or to payment of a fine of not more than $10,000, or both.
27.13 	(c) (d) A person who unlawfully possesses any amount of a synthetic cannabinoid is 
27.14 	guilty of a misdemeanor.
27.15 	(d) (e) Notwithstanding any contrary provision in sections 152.021 to 152.025, this 
27.16 	subdivision describes the exclusive penalties for the sale and possession of synthetic 
27.17 	cannabinoid.

27.18 	EFFECTIVE DATE. This section is effective August 1, 2012, and applies to crimes 
27.19 	committed on or after that date.